These trials focused on six clinical indications for the use of FXI inhibitors which were total knee arthroplasty (TKA), end-stage renal disease (ESRD), atrial fibrillation (AF), acute non-cardioembolic ischemic stroke, acute ischemic stroke, or high-risk transient ischemic attack (TIA) and acute myocardial infarction. Here, F11 is linked to transient ischemic attack.